Polyamide (peptide) nucleic acids conjugated with membrane-penetrating peptide are potential antisense therapeutic agents because of their unique chemical properties, high target specificity, and efficient cellular uptake. However, studies of their potential toxicity in animal models are lacking. In this study, we evaluated the toxicity of the response of Balb/C mice to anti-HIV-1 PNA TAR -penetratin conjugate targeted against the transactivation response (TAR) element of HIV-1 LTR. A single i.p. dose of 600 mg/kg of body weight was lethal, killing all mice within 72 hours. However, death did not occur after single doses of 100 and 300 mg/kg, although all mice experienced initial and transitory diarrhea and loss of agility. Repeated daily doses of 10, 30, and 100 mg/kg were well tolerated by mice during 8 days of treatment, although daily doses of 100 mg/kg caused diarrhea during the first 4 days of treatment. During 8 weeks of follow-up, mice fully recuperated. Serositis was observed in the spleens, livers, and kidneys at the ninth day of treatment, but not after the follow-up period. Necropsies, clinical chemistry studies, and hematological parameters demonstrated normal function of the major organs and no irreversible damage to the mice. These observations indicate that the PNApeptide conjugate would be nontoxic at probable therapeutic doses and thus support its therapeutic potential as an antisense drug.
INTRODUCTION I
NHIBITION OF THE EXPRESSION or function of targeted genes is the rationale for gene-specific therapeutics. The approach using sequence-specific peptide nucleic acid (PNA) against the target gene is viewed as one of the consensus models for antisense gene therapy (Nielsen et al., 1991; Koppelhus and Nielsen, 2003) . PNA molecules, which have no sugar phosphate backbone, are completely resistant to cellular nucleases and proteases, and display higher affinity to their complementary nucleic acid sequences than do normal oligo DNA or RNA (Nielsen et al., 1991) . Because of these properties, great hopes have been on PNA as a potent antisense molecule for use against a variety of cancers, viral and bacterial infections, and different metabolic disorders (Branden et al., 1999; Sazani et al., 2002; Tan et al., 2005; Maier et al., 2006) . Earlier, we showed that PNAs targeting the primer binding site and A-loop sequences in the U5-PBS region of the HIV-1 genome block the initiation of reverse transcription (Lee et al., 1998) by destabilizing the natural tRNA 3 Lys primer from the viral genome, and thus strongly inhibit HIV-1 replication (Kaushik et al., 2001; Kaushik and Pandey, 2002) . We have further demonstrated not only that PNA targeted to the transactivation response (TAR) element of HIV-1 LTR can prevent Tat-TAR interaction and block Tat-mediated transactivation of HIV-1 LTR transcription (Mayhood et al., Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, Newark, NJ 07103. *The first two authors contributed equally to this work. 2000 ), but also that, when transfected into HIV-1-infected cells, it effectively blocks HIV-1 production (Kaushik et al., 2002b) . These studies clearly demonstrated the anti-HIV-1 therapeutic potential of this class of compounds, which can successfully be used to target multiple critical regions of the HIV-1 genome to block viral replication and production.
On the other hand, the low solubility and poor cellular uptake of PNA in the living system has been a consistent impediment to the development of this antisense molecule as a therapeutic agent (Koppelhus and Nielsen, 2003) . Various efforts have been made using different strategies to improve the solubility and uptake of the molecule in cell-culture systems, as well as in vivo (Aldrian-Herrada et al., 1998; Kaushik et al., 2002a; Koppelhus and Nielsen, 2003; Chaubey et al., 2005; Chiarantini et al., 2005; Tripathi et al., 2005 Tripathi et al., , 2007 Maier et al., 2006) . We have used membrane transducing peptides (MTD) as the vector to deliver PNA cargo into cells. The conjugation of anti-HIV-1 PNAs with MTD peptides improved their solubility and provided rapid uptake by lymphocytes in a cell-culture system. Supplementation of these anti-HIV-1 PNA-MTD peptide conjugates in the HIV-1-infected cell culture effectively blocks HIV-1 replication and viral production (Kaushik et al., 2002a; Chaubey et al., 2005; Tripathi et al., 2005 Tripathi et al., , 2007 . We have further shown that anti-HIV-1 PNA-MTD peptide conjugates are not only antiviral, but also potently virucidal, having the ability to enter the virion particles and render them noninfectious Tripathi et al., 2005 Tripathi et al., , 2007 . However, to establish these molecules as effective drugs, issues such as toxicity, dose tolerance, acute lethal dose, and possible immune response must be addressed in vivo. Little or no information addressing these issues is currently available for this class of compounds. The present study was undertaken to evaluate the toxicity, dose tolerance, and lethal dose of a 16-mer anti-HIV-1 PNA TAR -penetratin peptide conjugate targeted against the TAR region of HIV-1 LTR.
MATERIALS AND METHODS
PNA TAR -penetratin conjugate was synthesized by BioSynthesis, Inc. (Lewisville, TX). The synthesis of PNA (TCC-CAG-GCT-CAG-ATC-T) and penetratin (RQIKI-WFQNRRMKWKKY) was performed in tandem, and the resulting conjugate had covalent linkage via an ϪO-spacer (ethylene glycol linker). The conjugate had a molecular mass of 6828, with purity greater than 90% as determined by C-18 reverse phase HPLC. Although trifluoroacetic acid (TFA) was removed by repeated lyophilization after dissolving in 70% methanol, traces of TFA may have remained in the sample that may add to the toxic effect of the conjugate. However, pH of the lyophilized conjugate dissolved in sterile sodium phosphate-buffered saline solution to a final concentration of 4.3 mM was found to be 7.4. Further, the conjugate had not shown any toxic effect in our cell culture experiments at 10 M concentration, as judged by 3 H-thymidine incorporation assay (unpublished results).
The solubility of the conjugate preparation was examined at 4.5 mM in 100 L sodium phosphate buffered saline solution (pH 7.4) containing 50% of mouse intraperitoneal fluid. The solution was incubated at 37°C for 6 hours and then centrifuged at 15,000 ϫ g for 30 minutes at room temperature to detect any insoluble matter or precipitate. The solution remained clear before and after the centrifugation, suggesting that the conjugate was soluble under condition analogous to IP environment. The conjugate remained soluble at 4.5 mM concentration in similar buffered solution containing 10% fetal calf serum. Thus, the solubility of this conjugate with pyrimidine bases Ͼ60% was significantly high.
Animals
Six-to-eight-week-old male Balb/c mice were purchased from Taconic Farms, Inc. (Hudson, NY) and quarantined for 2 weeks before the start of the experiment. The weight variation of individual mice was within Ϯ 10% of the mean body weight. The mice were fed LabDiet certified Rodent Diet. Food and water were available ad libitum. The mice were housed in a room with a temperature of 70 Ϯ 3°F, relative humidity of 31%-62%, and a 12-hour light/dark cycle. All husbandry conditions and experiments were performed according to the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at UMDNJ. Every measure was taken to ensure the welfare of the animals at all times during the course of this study.
Animal dosing
We chose mice randomly and grouped them five per cage for a multiple-dose toxicity study. Four groups of mice, labeled A, B, C, and D, were injected i.p. with PNA TAR -penetratin conjugate at respective doses of 0, 10, 30, and 100 mg/kg of body weight in a total volume of 200 L of phosphate-buffered saline every 24 hours for 8 consecutive days. The weight of each mouse was monitored every other day. Mice were also examined twice a day to monitor their behavioral activities and any apparent abnormalities. After 8 days of injections and monitoring, two mice from each group were sent to MU Research Animal Diagnostic Laboratory (Columbia, MO) for gross necropsy examination. The weight and behavioral activities of the remaining animals were regularly monitored for 8 weeks. At that time, two more mice were sent for necropsy examination and to assess their recovery from the damage suspected to have occurred during the 8 days of treatment.
Assessment of toxicity
During the 8 days of IP administration, we observed mice daily with respect to body weight, food, and water consumption, movements, hair loss, the condition of skin, eyes, and mucous membranes, and for the occurrence of convulsions, diarrhea, lethargy, or other abnormalities. The gross necropsy studies on day 9 and after 8 weeks of follow-up included examination of major organs, body weight assessment, and histopathology, as well as measurements of urea nitrogen, creatinine, sodium, potassium, chloride, albumin, total bilirubin, alanine transferase (ALT), and alkaline phosphatase (ALP), done on an Olympus AU 4000 analyzer. Hematology was also performed; all red and white blood cell counts were done on a Cell Dyne (Abbott, Abbott Park, IL) analyzer. The remaining mice were kept for the next 2 months under the same conditions, but without additional injections. All of the same parameters were evaluated in these mice to assess their recovery from toxicity, if any, due to the 8 days of injections PNA TAR -penetratin conjugate.
Tissue stability of PNA TAR -penetratin conjugate
Balb/c mice IP injected with PNA-O-penetratin (30-mg/kg) in saline solution were euthanized at 1, 6, 12, and 24 h time points. Kidney and liver tissues were collected, washed with saline solution, and homogenized in a buffer (1.5 mL/g tissue) consisting of 20 mM Tris, pH 7.5, 0.1 M EDTA, and 0.15% NP-40. Samples were centrifuged at 14,000 rpm for 10 minutes. The supernatant was acidified to pH 4.0 with 5% TFA and centrifuged again at 14,000 rpm for 10 min. The clear supernatant was applied on disposable Sep-Pak reverse phase C 18 cartridges (Waters, Milford, MA) preequilibrated with 5% acetonitrile in 0.1% TFA. The column was washed extensively with 5% acetonitrile/0.1% TFA and the PNA bound to it was eluted at 60% acetonitrile in 0.1% TFA at 50°C. An aliquot of each sample was analyzed by mass spectrometry using Applied Biosystems 4700 Proteomics Analyzer 7000 (Applied Biosystems, Bedford, MA). The remaining samples were lyophilized, dissolved in phosphatebuffered saline solution, and subjected to gel-retardation assay as described before (Chaubey et al., 2007) .
Acute dose toxicity
For this study, 6-8-week-old male Balb/c mice, divided into three groups of four mice, were injected i.p. with PNA TAR -penetratin conjugate at respective doses of 0, 100, 300, and 600 mg/kg body weight. The dose of 600 mg/kg of body weight was split into two equal doses of 200 L of 4.3-mM solution, administered at a 600-minute interval. This was essential to avoid sudden shock due to localized high concentration of the conjugate. After injection, animals were observed for 15 days. Evidence of toxic effects was assessed by clinical observation and by the death of any mice. Mice that died were subjected to gross necropsy.
RESULTS

Acute intraperitoneal toxicity of PNA TAR -penetratin conjugate in mice
After mice were given a single dose of PNA TAR -penetratin at 100 (group B), 300 (group C), or 600 (group D) mg/kg of body weight, all of the mice in groups C and D appeared drowsy and weak, moving little in their cages, showing a very low response to sound, and developing diarrhea. Group B mice also had mild diarrhea during the first 24 hours after injection. Two mice from group D died on day 2 after injection; a third mouse died on day 3. Group B and group C mice showed signs of recovery from day 1 and 2, respectively. From day 4 onward, the activity of group C mice was similar to that of control mice. Therefore, the LD 50 of the PNA TAR -penetratin conjugate was determined to be Յ600 mg/kg body weight. Autopsies on the dead mice from group D did not reveal any gross findings that could be correlated with the acute lethal dose of the conjugate. We presume that the death of these mice may have been the result of diarrhea-induced dehydration caused by the acute dose of the conjugate.
Repeat-dose IP toxicity of PNA TAR -penetratin conjugate on mice
After administering repeat i.p. doses of the PNA TARpenetratin conjugate at 0 (group A), 10 (group B), 30 (group C), and 100 (group D) mg/kg body weight every 24 hours for 8 consecutive days, no behavioral changes were observed in mice in groups A and B. However, we noted a mild loss of agility in group C mice and moderate loss of agility in group D mice. At 12 hours after the second injection, group D mice looked frail and drowsy and maintained a hunched posture. Their coats became ruffled and their ear lobes were reddish and tender. In addition, all group D mice had diarrhea during the first 4 days of injection, and decreased their water and food consumption. We recorded a distinct recovery in their physical activity from day 5 onward. The diarrhea stopped and all the mice showed improving physical activity. We recorded no significant loss of body weight during the 8 days of the study period. All mice regained normal behavioral activity and agility within less than a week after
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the last injection. After 8 weeks of monitoring, two mice from each group were sacrificed for necropsy examination. We kept the remaining mice under observation for 60 more days. No mouse in any group died during the study period, suggesting that all of the dose ranges were well tolerated.
We examined the stability of IP administered PNA TARpenetratin conjugate in mouse organs in group C mice (30 mg/kg body weight). Following IP injection, mice were euthanized at different time points and PNA TARpenetratin conjugate isolated from the kidney and liver were subjected to gel-retardation assay after binding to its 32 P-labeled target sequence (82 mer TAR DNA). The gel retardation of the 32 P-labeled target sequence suggested that the PNA component of the conjugate may have remained intact. The mass spectroscopy of the conjugate isolated from liver and kidney tissue indicated several mass peaks of the conjugate due to truncation of its peptide components (Fig. 1 ). PNA alone has been shown to be highly stable in tissue and cellular extracts because it is completely resistant to proteases and nucleases (Demidov et al., 1994; Jansen and Richardson, 2000) .
Necropsy and histopathology of the kidney, liver, and spleen
In our pharmacokinetic studies following i.p. injection of 125 I-labeled PNA TAR -penetratin conjugate (10 mg/kg body weight) in mice, the kidney, liver, and spleen were the major sites of its accumulation (Ganguly et al., unpublished data) . We further noted biphasic (rapid and slow) clearance profile of the conjugate from mouse organs. A similar biphasic clearance profile was also reported for unconjugated naked PNA administered via an intravenous route (McMahon et al., 2002) . We therefore performed histopathologic analysis of the kidney, liver, and spleen after 24 hours of the last injection (ninth day) and after 8 weeks (60th day) of recovery ( Fig. 2) . The necropsies of group B mice given repeated doses of 10 mg/kg body weight were identical to those of group A (control) mice, and therefore were excluded from Figure  2 . Histopathologic analysis of kidneys on day 9 revealed a few scattered focal areas of mild mixed inflammatory visceral serositis in group C mice and more prominent areas of visceral serositis in the kidneys of group D mice. However, inflammatory visceral serositis was not observed in the necropsies performed on the 60th day of the recovery period (Fig. 2) .
We noted similar focal areas of mild to moderate mixed inflammatory visceral serositis in the livers of group C and D mice in necropsies performed on the ninth day of the study. These areas within the liver capsule were characterized by the presence of macrophages with basophilic cytoplasm and intracytoplasmic vesicles containing granular material. We noted an approximately 8% increase in the weight of livers from group C mice and weight increases as high as 25% in the livers of group D mice on the ninth day (Table 1) . However, by the 60th day of recovery liver weight in both groups of mice corresponded to that in control mice. Moreover, no liver lesions were found in the necropsies performed after 60 days of recovery.
The spleens of group C and D mice examined on the ninth day of the study had mild multifocal areas of mixed inflammatory visceral serositis with mild hematopoesis (Fig. 2) . These lesions were more prominent in group D mice than in group C mice, with moderate hematopoesis and moderate to generalized white-pulp hyperplasia. We also noted an approximately 8% increase in the weight of spleens in group C mice; in group D mice there was distinct splenomegaly with a 72% increase in the weight of spleens (Table 1) . By the 60th day of recovery, spleen weight in both groups of mice had returned to the level in control mice (Table 1 ). In both group C and D mice, splenic lesions were absent by the 60th day of recovery.
Clinical chemistry and hematology
We evaluated various clinical parameters indicative of the appropriate functioning of mice's test organs. In the first blood analysis, done 24 hours after the last injection (ninth day), we found that in all groups the blood levels of urea nitrogen, creatinine, sodium, potassium, chloride, albumin, bilirubin, and ALP were within normal range, suggesting that the overall function of major organs was not affected by the conjugate. The only exception was the elevation in levels of ALT, especially in group D mice, in which ALT was 2.5-fold higher than its upper normal limit ( Table 2) . We also noted a moderate 1.3-fold increase in ALT in group C mice. In the second blood analysis, done at the end of the 8-week recovery period, the ALT levels had returned to almost normal level in both group C and D mice. All other parameters were similar to those in the first blood analysis. This clinical chemistry parameter is indicative of the extent of gross normal function of the kidney and liver.
Analysis of hematological parameters demonstrated that red and white blood cells and percentages of monocytes, basophils, lymphocytes, and neutrophils remained within normal range on both the 9th day and 60th day (Table 3) . In group C mice, there were some clumped platelets and a few Howell-Jolley bodies with mild polychromasia; in group D mice, the polychromasia was moderate. After 8 weeks of recovery, these changes were no longer present in either group.
Bone marrow aspirate
Bone marrow aspirate was examined to determine whether any blood-related disorder or malignancy had
FIG. 1.
Gel retardation and mass spectroscopy of PNA TAR -O-penetratin conjugate isolated from mouse organs. Following i.p. injection of the conjugate in group C mice (30 mg/kg body weight), mice were euthanized at different time points and the conjugate accumulated in kidney and liver tissue was isolated as described in the Materials and Methods. For gel retardation (top panel) 5Ј-32 P-labeled 82-mer TAR-DNA (5 nM) was incubated with the isolated conjugate in the binding buffer (50 mM Tris Ǟ HCl, pH 7.8, and 5 mM MgCl 2 ) for 30 minutes at room temperature. Gel loading dye containing 0.25% bromophenol blue and 30% glycerol was added to it and loaded on an 6% polyacrylamide native gel. The gel was run for 3 hours at 150 V in 1ϫ Tris-borate-EDTA buffer, dried, and subjected to Phosphor-Imager analysis (Molecular Dynamics, Sunnyvale, CA). The mass spectrometry analysis of the conjugate isolated from kidney and liver tissue was carried out on Applied Biosystems 4700 Proteomics Analyzer 7000. occurred in mice as a result of multiple dosing with PNA TAR -penetratin conjugate. All four groups had essentially identical profiles, the exception being slight variation in the ratio of myeloid erythroblasts (M:E ratio) in different groups. The M:E ratios in groups A, B, C, and D were, respectively, 1.5:1, 1.5:1, 2:1, and 2.2:1, with both cell lines well represented and progressing to maturity in an orderly fashion. Few adequately cellular bone marrow particles were seen, and megakaryocytes were readily observed. Low numbers of small lymphocytes were present in all the groups. No organisms, neoplastic cells, or cytopathologic abnormalities were observed. The examination of bone marrow aspirate after 8 weeks of recovery showed no significant difference from the previous observations except that the M:E ratio was almost 1:1 in all four groups.
DISCUSSION
This is the first in vivo study evaluating the acute toxicity of single and repeat doses of PNA TAR -penetratin conjugate in mice. Toxicity and undesirable side effects of penetratin alone have not been detected in most in vivo applications (see review by Langel and Zorko, 2005) . Recently, i.p. administration of penetratin alone in rat has been shown to be beneficial by inhibiting the expression of proinflamatory genes and improving the histological parameters of pancreatitis and associated oxidative stress (Letoha et al., 2006) . Earlier, we have shown that PNA TARpenetratin conjugate targeting the transactivating response element (TAR) of HIV-1 LTR efficiently enters into the cells and blocks Tat-mediated transactivation of HIV-1 transcription and replication (Kaushik et al., 2002a; Chaubey et al., 2005; Tripathi et al., 2005) . Besides having antiviral activity, PNA TAR -penetratin conjugate contains potent anti-HIV-1 virucidal activity. HIV-1 virions become noninfectious after only brief exposure to the conjugate. The present study suggests that Յ0.6 g/kg is a lethal dose of PNA TAR -penetratin conjugate. All mice given a single dose of 0.6 g/kg died within 72 hours. In contrast, a single dose of 0.3 g/kg was well tolerated; none of the mice in this group died. These observations suggest that the LD 50 of the conjugate in Balb/c male mice is Ͼ0.3 g/kg body weight and Ͻ0.6 g/kg body weight. In another study, pharmacokinetic studies of intravenously administered 18-mer PNAE conjugated with nuclear localization sequence was carried out at a single dose of 200 nmol/mouse (ϳ58.5 mg/kg) was found to be well tolerated without any apparent toxic effect on mice (Boffa et al., 2005) . The i.p. administration of 24-mer relA antisense phosphorothioate oligodeoxyribonucleotides (PS-ODN) at a dose of 0.15 g/kg body weight caused 7 of 12 mice to die (Sarmiento et al., 1994) , while intravenous injection of 17-mer AR177 oligodeoxyribonucleotide at a single dose of 1.5 g/kg caused the death of 4 of 12 mice (Wallace et al., 2000) . At this stage it is not clear if the observed lethal dose of PNA TAR -penetratin is unique to this conjugate or common to other PNA-peptide conjugates.
Our repeat dose toxicity studies suggest that PNA TARpenetratin conjugate is nontoxic in mice within a dose range up to 100 mg/kg body weight. At a repeated dose of 100 mg/kg, a notable but reversible effect was the onset of diarrhea, resulting in reduced agility and physical activity. However, this occurred only at the beginning of the treatment, disappearing between days 4 and 8 of drug administration. There was no significant change in the weight of mice during treatment. Moreover, no mouse died during treatment or the 60-day follow-up period. In another study, i.p. administration to mice of an 18-mer PNA-4Lys conjugate at 50 mg/kg dose had a sequencespecific antisense effect in mouse organs (Pierce et al., 2005) . However, the toxic effect of the conjugate at this i.p. dose was not evaluated.
In this context, our finding that repeated IP administration of PNA TAR -penetratin conjugate at 100 mg/kg is well tolerated, and eliciting negligible toxic effects on mice is important. Group D mice receiving repeated doses of 100 mg/kg showed signs of splenomegaly with serositis in the first necropsy without any significant change in organ weight. However, the necropsies done after 60 days of recovery were normal, indicating the reversibility of these changes. It should be noted that serositis occurred in these organs after the mice had been given repeated dose far in excess of the expected therapeutic doses for this class of compounds. Although Wallace et al. (2000) found that injection of high doses of AR177 DNA oligonucleotide caused renal toxicity including nephropathy and tubular necrosis in mice, we did not observe such changes with PNA TAR -penetratin conjugate in any mice. Another phosphorothioate DNA oligonucleotide, OL(1)p53, when intravenously administered to monkeys at 8.3 mg/kg, caused death due to decreased blood pressure (Cornish, 1993) . However, Cornish found that death did not occur when this agent was administered by slow infusion. It is likely that the pharmacokinetic responses and toxic effect of drugs will vary with the route and rate of administration in different species (Cornish, 1993; Black et al., 1994) .
Clinical chemistry analyses on the 9th and 60th days of the study showed normal levels of all values except those for ALT, which were marginally elevated (1.5-1.25-fold) in mice in groups C and D. The normal levels of alkaline phosphatase implied that there had been no significant damage to liver cells. Overall, these findings suggest the maintenance of normal cellular function at repeated high doses of the PNA TAR -penetratin conjugate. Similar blood chemistry results have been reported in response to the
FIG. 2.
Effect of PNA TAR -penetratin conjugate on mouse organs. Male Balb/C mice in groups C and D received PNA TAR -penetratin conjugate at respective doses of 30 or 100 mg/kg of body weight every 24 hours for 8 consecutive days. Control mice in group A received only vehicle. Two mice from each group were euthanized on the 9th day; the remaining mice were euthanized on the 60th day after the first i.p. injection and subjected to whole-body necropsy. Thin cross-sections of the spleen, kidney, and liver were fixed and stained with hematoxylin, then evaluated by light microscopy to identify any significant abnormalities in response to the conjugate. Each panel shows sections from these mice. Visceral serositis is indicated by arrows.
administration of DNA oligonucleotides in mice (Wallace et al., 2000; Rembach et al., 2004) . Most of the hematological parameters determined on the 9th and 60th days were within normal limits in all mice, suggesting that the PNA TAR -penetratin conjugate had no deleterious effects on the health and functions of mouse organs. Similarly, the examination of bone marrow aspirate revealed no abnormality in any mice. The difference in the M:E ratio was observed in all groups of mice only in ninth day aspirate, suggesting that the PNA TAR -penetratin conjugate had no significant influence on the immune system. However, comprehensive studies of the immunomodulator effects of PNA TAR -penetratin conjugate will be required to confirm this contention. Potential of PNA as an anti-AIDS (Kaushik et al., 2002a; Chaubey et al., 2005; Tripathi et al., 2005 Tripathi et al., , 2007 and anticancer agent (Knudsen and Nielsen, 1997; Boffa et al., 2005) has been well documented. Inhibition of growth of Burkitt's lymphoma cells in SCID mice by PNA complementary to intronic E sequences has also demonstrated anticancer therapeutic potential of PNA . Furthermore, PNAE conjugated with nuclear localization sequence (NLS) was found to be nonimmunogenic in Burkitt's lymphoma cells, while a significant immune response was noted when coupled with an immunogenic carrier, keyhole limpet hemocyanin . It is expected that, similar to PNAE-NLS conjugate, PNA TAR -penetratin may also be nonimmunogenic, although penetratin alone has been shown to elicit a low but insignificant immune response in mice (Upadhyay et al., unpublished results) .
The modified backbone of oligonucleotides may greatly contribute to their pharmacokinetic behavior and, consequently, their prospects as potential antisense therapeutic molecules. It has been shown that the degree of hemodynamic alteration is dependent on the degree of thiation, and that total phosphorothioates cause more toxicity than do their partial counterparts (Henry et al., 1997) . A comparative study of PNA, phosphorothioate, and morpholino oligonucleotide with regard to their antisense activities on a common target in transgenic mice has shown that PNA, with its chargeless backbone, has stronger antisense and better pharmacokinetic behavior than do the other two oligonucleotides (Sazani et al., 2002) . Other studies comparing pharmacokinetic behavior of phosphodiester, phosphorothioate, and neutral methylphosphonate oligonucleotides support the potential utility of phosphorothioate and neutral methylphosphonate oligonucleotides as therapeutic agents in vivo (Agrawal et al., 1995; DeLong et al., 1997) .
In conclusion, this study demonstrates that PNA TARpenetratin conjugate, with its potential antiviral and virucidal activity against HIV, is nontoxic when used in therapeutic doses. However, further studies are needed to determine its organ-specific toxicity and pharmacokinetic behavior after administration through different routes in different animal models. In addition, the long-term effect of PNA drugs on the immune system, as well as on clinical chemistry, needs thorough study before their direct human use is initiated. Effect of repeat i.p. doses of PNA TAR -penetratin conjugate on mouse body and organ weights. Four groups of mice, A, B, C, and D, were injected i.p. with PNA TAR -penetratin conjugate at respective doses of 0 (vehicle only), 10, 30, and 100 mg/kg of body weight every 24 hours for 8 consecutive days. Mean body weight was recorded on alternate days for the first 9 days and periodically thereafter for 8 weeks. Two mice from each group were euthanized on the ninth day; the remaining mice were euthanized after 8 weeks and subjected to whole-body necropsy. The weights of livers, kidneys, and spleens were recorded at both time points. The mean weight of the whole bodies and the vital organs are shown. The numbers in parentheses are the standard deviations for each cohort. Mice were treated as described in the legend for Table 1 . Two animals from each group were euthanised on the ninth day and the remainder at 8 weeks. At these times, levels of urea nitrogen, creatinine, sodium, potassium, chloride, albumin, total bilirubin, ALT, and ALP were measured. As shown, most of the parameters were within or close to normal limits in all the four groups at both time points. Only the ALT level was elevated above the normal limit in all groups except group B, treated with 10 mg/kg of the conjugate. Mice were treated and euthanized as described in the legend for Table 1 . The mean hematologic values for these mice are shown here. The numbers in parentheses indicate their respective standard deviations. Most of the parameters among leucocytes and RBCs were within normal limits. Eosinophil was elevated in groups B and C on the ninth day, but receded to normal limits after 8 weeks. Hemoglobin and hematocrit levels were slightly elevated above normal limits in all groups of mice, possibly because of the slightly higher basal level of RBCs in these animals (MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration).
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